

**UNIVERSITÀ DEGLI STUDI DI PARMA**

Dipartimento di Farmacia

Dottorato di ricerca in  
FARMACOLOGIA E TOSSICOLOGIA SPERIMENTALI  
CICLO XXV

**DISCOVERY, DEVELOPMENT AND  
PHARMACOLOGICAL CHARACTERIZATION OF  
SMALL MOLECULES INTERFERING WITH EPH-  
EPHRIN SYSTEM**

Coordinatore:

Chiar.ma Prof.ssa ELISABETTA BAROCELLI

Tutor:

Chiar.mo Prof. MASSIMILIANO TOGNOLINI

Chiar.ma Prof.ssa ELENA PASQUALE

Dottoranda:

Dott.ssa IFTIIN HASSAN MOHAMED

TRIENNIO ACCADEMICO 2010-2012



# INDEX

<b>INTRODUCTION</b> .....	1
<b>1. The Eph-ephrin system</b> .....	1
1.1 Structure and signal activation.....	1
1.2 Crosstalk with other pathways.....	3
1.3 Cellular functions.....	4
1.4 Eph-ephrin system in physiology.....	6
1.4.1 Embryogenesis.....	6
1.4.2 Central Nervous system (CNS).....	8
1.4.3 Platelet aggregation.....	9
1.4.4 Bone homeostasis.....	10
1.4.5 Intestinal homeostasis .....	11
1.4.6 Immune system.....	12
1.4.7 Inflammation .....	13
1.4.8 Glucose balance.....	13
1.4.9 Angiogenesis.....	14
1.5 Eph-ephrin system in cancer progression .....	16
1.5.1 Colon cancer.....	18
1.5.2 Breast cancer.....	18
1.5.2 Prostate cancer.....	19
<b>2. Targeting the Eph-ephrin system: emerging strategies</b> .....	20
2.1 Kinase inhibitors.....	21

<b>2.2 Molecules targeting on the LBD.....</b>	<b>23</b>
<b>2.2.1 Peptides .....</b>	<b>23</b>
<b>2.2.2 Lithocholic acid (LCA) .....</b>	<b>24</b>
<b>2.2.3 Salicylates.....</b>	<b>25</b>
<b>2.2.4 Doxazosin .....</b>	<b>25</b>
<b>2.2.5 Polyphenols .....</b>	<b>26</b>

<b>AIM.....</b>	<b>27</b>
-----------------	-----------

<b>MATERIALS AND METHODS.....</b>	<b>28</b>
-----------------------------------	-----------

<b>1. Reagents .....</b>	<b>28</b>
<b>2. Cell culture .....</b>	<b>28</b>
<b>3. ELISA binding assay and <math>k_i/IC_{50}</math> determination .....</b>	<b>28</b>
<b>4. Cell lysates .....</b>	<b>29</b>
<b>5. Evaluation of EphA2, EphB4, EGFR phosphorylation.....</b>	<b>30</b>
<b>6. Kinase assay .....</b>	<b>30</b>
<b>7. MTT assay.....</b>	<b>30</b>
<b>8. LDH assay .....</b>	<b>31</b>
<b>9. Retraction assay .....</b>	<b>31</b>
<b>10. Tube formation assay .....</b>	<b>31</b>
<b>11. Surface Plasmon Resonance (SPR).....</b>	<b>32</b>
<b>12. Statistical analysis.....</b>	<b>32</b>

<b>RESULTS .....</b>	<b>33</b>
----------------------	-----------

<b>1. Preliminary data: hit discovery .....</b>	<b>33</b>
---	-----------

1.1 LCA is a competitive and reversible Eph receptor ligand .....	33
1.2 LCA inhibits Eph-kinase phosphorylation .....	36
1.3 LCA does not affect the Eph kinase domain.....	37
1.4 LCA antagonism is specific for the Eph-ephrin system .....	37
<b>2. Hit to lead.....</b>	<b>39</b>
2.1 LCA binds EphA2 and not ephrin-A1 .....	39
2.2 Identification of the pharmacophoric scaffold .....	42
2.2.1 Cholanic acid and isolithocholic acid inhibit EphA2-ephrinA1 binding.....	45
2.2.2 Surface plasmon resonance (SPR) binding analysis of cholanic acid and isolithocholic acid to Eph receptors.....	48
2.2.3 Cholanic acid and isolithocholic acid inhibit Eph receptor phosphorylation at not cytotoxic concentrations.....	50
2.2.4 Cholanic acid does not inhibit EphA2 kinase activity .....	52
2.2.5 Cholanic acid and isolithocholic acid antagonism is specific for Eph receptors .....	53
2.2.6 Cholanic acid and isolithocholic acid block EphA2-mediated PC3 retraction .....	53
2.3 LCA amino acid derivatives .....	55
2.3.1 Glycolithocholic acid .....	55
2.3.2 Structure-activity relationship of amino acid derivatives .....	57
2.3.3 A new competitive and reversible ligand for Eph receptors: L-Tryptophan LCA (L-TrpLCA) .....	60
2.3.4 L-Trp LCA is an antagonist of the EphA2 receptor.....	62
2.3.5 L-Trp LCA does not affect EGFR phosphorylation .....	64
2.3.6 L-Trp LCA inhibits EphA2 –mediated PC3 cells retraction .....	65
2.2.7 L-Trp LCA blocks angiogenesis in HUVEC without cytotoxicity .....	66

<b>3. Polyphenols</b> .....	68
<b>3.1</b> Nine extracts inhibit EphA2-ephrinA1 binding .....	69
<b>3.2</b> Extracts inhibit EphA2 phosphorylation at not cytotoxic concentrations .....	71
<b>3.3</b> Extracts do not interfere with EGFR activity .....	73
<b>DISCUSSION AND CONCLUSIONS</b> .....	74
<b>1. LCA and LCA derivatives</b> .....	74
1.1 Discovery of a hit compound: LCA .....	74
1.2 Hit to lead: LCA derivatives.....	76
<b>2. Polyphenols</b> .....	81
<b>BIBLIOGRAPHY</b> .....	85
<b>ACKNOWLEDGMENTS</b> .....	103